Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Mathematical models are used to predict many natural phenomena around us, including population growth, the weather and the movement of planets. In medicine, scientists are using models to predict the ability of drugs to reach certain locations in the body, particularly the brain.
The blood–brain barrier (BBB) acts as a barricade that prevents harmful toxins and substances in the blood from reaching the brain. While this barrier is necessary for preserving a healthy brain, a major drawback is that new drugs developed to treat neurological disorders, such as Alzheimer's disease, might not be able to cross into the brain at high enough levels to be effective.
A study led by Dr. Donald Weaver, Director of the Krembil Research Institute, revealed a new strategy that can facilitate the design of medications for neurological disorders.
Dr. Weaver's group developed a computational model called "BBB Score" that predicts the likelihood of a drug penetrating through the BBB using information about the drug's physical and chemical properties.
The new score was proven to be better at predicting entry for selected drugs than other conventional approaches.
These findings suggest that the "BBB Score" could be used to supplement other models currently used in drug development programs. It has been classified in F1000Prime as a technical advance and being of special significance in its field.
"The BBB Score is a much needed tool that will improve the effectiveness of drug development efforts, while saving time and resources," says Dr. Weaver.
This work was supported by the Krembil Foundation. DF Weaver holds a Tier 1 Canada Research Chair in Protein Misfolding Diseases.
Read more about the study